GenesisCare Oxford Brings the Benefits of
Continuous Soft-Tissue Imaging and Adaptive Treatment Delivery
to UK Cancer Patients
CLEVELAND, Dec. 17, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today that the first MRIdian
MRI-guided radiotherapy system in the United Kingdom (UK) – located at GenesisCare
Oxford – has begun patient treatments. MRIdian combines high
definition MRI imaging with linear accelerator radiation therapy to
allow clinicians to visualize and adapt therapy as they treat
tumors throughout the body.
The first patient treated with MRIdian at Oxford was treated for prostate cancer using
fully adapted stereotactic body radiation therapy (SBRT). SBRT
involves the delivery of higher doses of radiation than
conventional radiation therapy in fewer treatment sessions. Using
MRIdian's adaptive therapy capabilities, the radiation plan is
optimized and adjusted to address movement and anatomical changes.
This helps to ensure maximum coverage is achieved while sparing
nearby tissue and organs in order to significantly reduce side
effects.
"MRI-guided radiotherapy is the most exciting development in
advanced radiotherapy we've seen in years," said Philip Camilleri, M.D., Consultant Clinical
Oncology & GenesisCare Clinical Director of Uro-Oncology.
"Bringing the MRIdian Linac to Oxford and other centers within the
GenesisCare network delivers on our promise to provide the best
available cancer care. This remarkable system allows high-dose,
highly accurate treatment to be provided to every patient treated,
every day. Doing so will mean patients will have to make fewer
trips to complete their treatment."
Initially, the clinical team at Oxford will focus their MRI-guided radiation
therapy program on treating organ-confined prostate cancer where
they believe MRIdian's precision offers significant benefits in
reducing treatment side effects. In the coming months, the program
will be expanded to other targets throughout the body, including
pancreatic and liver tumors, where MRIdian's continuous imaging and
adaptive therapy capabilities are particularly critical.
The MRIdian at GenesisCare in Oxford is the first system to be installed in
the UK, but more will follow. As part of its agreement with
ViewRay, the company is committed to the deployment of multiple
MRIdian systems within its network. GenesisCare will also work in
collaboration with the University of
Oxford to develop research protocols that will allow
National Health Service patients to access MRIdian treatment. As
the largest provider of private cancer services in the UK,
Spain and Australia, GenesisCare operates more than 130
oncology and cardiology centers in total, offering radiotherapy at
14 centers in the UK, 21 centers in Spain and 30 centers in Australia.
ViewRay's MRIdian system has already been installed at 30
leading hospitals around the world where it is being used to treat
a wide variety of solid tumors and is the focus of numerous ongoing
clinical trials. MRIdian has been the subject of hundreds of
peer-reviewed publications, scientific meeting abstracts and
presentations. More than 6,500 patients have been treated with
MRIdian. For a list of treatment centers, please visit:
https://viewray.com/mridian-locator.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets
the MRIdian® radiation therapy system. MRIdian is built upon a
proprietary high-definition MR imaging system designed from the
ground up to address the unique challenges and clinical workflow
for advanced radiation oncology. Unlike MR systems used in
diagnostic radiology, MRIdian's high-definition MR was purpose
built to address specific challenges, including beam distortion,
skin toxicity, and other concerns that potentially may arise when
high magnetic fields interact with radiation beams. ViewRay and
MRIdian are registered trademarks of ViewRay, Inc.
About GenesisCare in the UK:
GenesisCare delivers holistic oncology care at 14 specialist
treatment centres in the UK, spanning radiotherapy, medical
oncology, diagnostics, theranostics and wellness services. It is
the largest provider of private cancer care services in the UK.
Over the next two years, GenesisCare plans to open five new centres
in the country, to increase patient access to world-class care when
and where it's needed. Treatment is currently delivered in
Birmingham, Bristol, Cambridge, Chelmsford, Elstree, Guildford, London, Maidstone, Milton
Keynes, Nottingham,
Oxford, Portsmouth, Southampton and Windsor.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Private Securities Litigation
Reform Act. Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, the rate of new orders,
upgrades and installations, ViewRay's financial guidance for the
full year 2019 and ViewRay's conference call to discuss its second
quarter results. Actual results could differ from those projected
in any forward-looking statements due to numerous factors. Such
factors include, among others, the ability to commercialize MRIdian
Linac System, demand for ViewRay's products, the ability to convert
backlog into revenue, and the timing of delivery of ViewRay's
products, the timing, results and other uncertainties associated
with clinical trials, the ability to raise the additional funding
needed to continue to pursue ViewRay's business and product
development plans, the inherent uncertainties associated with
developing new products or technologies, competition in the
industry in which ViewRay operates and overall market conditions.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to ViewRay's
business in general, see ViewRay's current and future reports filed
with the Securities and Exchange Commission, including its Annual
Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Reports on
Form 10-Q for the fiscal quarters ended March 31, 2019, June 30,
2019, and September 30, 2019,
as updated periodically by the company's other filings with the
SEC. These forward-looking statements are made as of the date of
this press release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
Logo -
https://mma.prnewswire.com/media/560662/ViewRay_Logo.jpg